C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
Table 4
OS benefit based on ORR using RECIST 1.1 scans and CRP changes at 6 weeks in OAK.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
OS benefit based on ORR using RECIST 1.1 scans and CRP changes at 6 weeks in OAK.